Could Anti‐Hypertensive Drug Therapy Affect the Clinical Prognosis of Hypertensive Patients With COVID‐19 Infection? Data From Centers of Southern Italy
BACKGROUND Coronavirus disease 2019 (COVID‐19) is the cause of a pandemic disease, with severe acute respiratory syndrome by binding target epithelial lung cells through angiotensin‐converting enzyme 2 in humans. Thus, patients with hypertension with COVID‐19 could have worse prognosis. Indeed, angi...
Main Authors: | Celestino Sardu, Paolo Maggi, Vincenzo Messina, Pasquale Iuliano, Antonio Sardu, Vincenzo Iovinella, Giuseppe Paolisso, Raffaele Marfella |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-09-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.120.016948 |
Similar Items
-
Implications of AB0 blood group in hypertensive patients with covid-19
by: Celestino Sardu, et al.
Published: (2020-08-01) -
Microalbuminaria in hypertension: a review
by: Mahesh Bhattarai, et al.
Published: (2012-12-01) -
A study of prognosis and outcome of COVID-19-infected hypertensive patients on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
by: M S Bharath, et al.
Published: (2024-01-01) -
Management of hypertension in patients with COVID-19: Implication of angiotensin-converting enzyme 2
by: Guang-Hong Jia, et al.
Published: (2021-01-01) -
Effect of an angiotensin-converting-enzyme inhibitor on the plasma concentration of cytokines and vasoactive molecules in patients with coronary heart disease and hypertension
by: A A Khadartsev, et al.
Published: (2017-12-01)